|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/31/19 Abiomed Inc 10-Q 9/30/19 79:11M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.12M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
48: R1 Document and Entity Information HTML 77K
25: R2 Condensed Consolidated Balance Sheets HTML 122K
34: R3 Condensed Consolidated Balance Sheets HTML 46K
(Parenthetical)
77: R4 Condensed Consolidated Statements of Operations HTML 81K
51: R5 Condensed Consolidated Statements of Comprehensive HTML 44K
Income
27: R6 Condensed Consolidated Statements of Stockholders' HTML 109K
Equity
36: R7 Condensed Consolidated Statements of Cash Flows HTML 122K
74: R8 Nature of Business HTML 28K
52: R9 Basis of Preparation and Summary of Significant HTML 33K
Accounting Policies
71: R10 Net Income Per Share HTML 126K
61: R11 Revenue Recognition HTML 125K
14: R12 Cash Equivalents, Marketable Securities and Fair HTML 468K
Value Measurements
41: R13 Property and Equipment HTML 62K
70: R14 Goodwill, In-Process Research and Development and HTML 144K
Other Assets
60: R15 Leases HTML 100K
13: R16 Accrued Expenses HTML 59K
40: R17 Stockholders' Equity HTML 27K
69: R18 Stock-Based Compensation HTML 214K
62: R19 Income Taxes HTML 96K
19: R20 Commitments and Contingencies HTML 41K
30: R21 Segment and Enterprise Wide Disclosures HTML 28K
73: R22 Basis of Preparation and Summary of Significant HTML 118K
Accounting Policies (Policies)
46: R23 Net Income Per Share (Tables) HTML 124K
18: R24 Revenue Recognition (Tables) HTML 91K
29: R25 Cash Equivalents, Marketable Securities and Fair HTML 468K
Value Measurements (Tables)
72: R26 Property and Equipment (Tables) HTML 62K
45: R27 Goodwill, In-Process Research and Development and HTML 137K
Other Assets (Tables)
20: R28 Leases (Tables) HTML 97K
28: R29 Accrued Expenses (Tables) HTML 57K
42: R30 Stock-Based Compensation (Tables) HTML 219K
16: R31 Income Taxes (Tables) HTML 92K
57: R32 Net Income Per Share - Additional Information HTML 27K
(Detail)
66: R33 Computation of Basic and Diluted Net Income Per HTML 52K
Share (Detail)
43: R34 Revenue Recognition - Schedule of Categorizes HTML 32K
Revenue by Major Business Line (Detail)
17: R35 Revenue Recognition - Schedule of Categorizes HTML 32K
Revenue by Major Geographical Location (Detail)
58: R36 Revenue Recognition - Terms - Additional HTML 38K
Information (Detail)
67: R37 Revenue Recognition - Deferred Revenue - HTML 29K
Additional Information (Detail)
44: R38 Cash Equivalents and Marketable Securities HTML 33K
(Detail)
15: R39 Investable Cash Equivalents and Marketable HTML 59K
Securities (Detail)
31: R40 Financial Instruments Measured at Fair Value HTML 67K
(Detail)
22: R41 Cash Equivalents, Marketable Securities and Fair HTML 31K
Value Measurements - Additional Information
(Detail)
53: R42 Valuation Method Used to Calculate Level 3 HTML 71K
Liabilities Measured at Estimated Fair Value of
Contingent Consideration Related to Acquisition
(Detail)
78: R43 Change in Fair Value of Contingent Consideration HTML 39K
as Determined by Level 3 Inputs (Detail)
32: R44 Components of Property and Equipment (Detail) HTML 49K
23: R45 Goodwill, In-Process Research and Development and HTML 66K
Other Assets - Additional Information (Detail)
54: R46 Carrying Value of Goodwill and Change in Balance HTML 29K
(Detail)
79: R47 Carrying value of In-Process Research and HTML 28K
Development (Detail)
33: R48 Summary of Other Assets (Detail) HTML 33K
21: R49 Equity Method and Other Investments Classified as HTML 33K
Other Assets (Detail)
11: R50 Carrying value of Other Investments (Detail) HTML 31K
39: R51 Supplemental Balance Sheet Information Related to HTML 32K
Operating Leases (Detail)
65: R52 Leases - Additional Information (Details) HTML 29K
56: R53 Maturities of Operating Lease Liabilities HTML 48K
(Details)
10: R54 Minimum Future Lease Payments (Detail) HTML 44K
38: R55 Accrued Expenses (Detail) HTML 45K
64: R56 Stockholders' Equity - Additional Information HTML 36K
(Detail)
55: R57 Stock-Based Compensation Recognized (Detail) HTML 34K
12: R58 Summary of Stock Option Activity (Detail) HTML 79K
37: R59 Stock-Based Compensation - Additional Information HTML 55K
(Detail)
76: R60 Summary of Weighted Average Grant-Date Fair Values HTML 39K
And Weighted Average Assumptions Used to Calculate
Fair Value of Options Granted (Detail)
50: R61 Summary of Restricted Stock Units Activity HTML 49K
(Detail)
26: R62 Income Taxes - Additional Information (Detail) HTML 33K
35: R63 Differences Between Statutory Income Tax Rate and HTML 44K
Effective Income Tax Rate (Detail)
75: R64 Commitments and Contingencies - Additional HTML 30K
Information (Detail)
49: R65 Segment and Enterprise Wide Disclosures - HTML 39K
Additional Information (Detail)
63: XML IDEA XML File -- Filing Summary XML 146K
47: XML XBRL Instance -- abmd-10q_20190930_htm XML 3.33M
24: EXCEL IDEA Workbook of Financial Reports XLSX 79K
6: EX-101.CAL XBRL Calculations -- abmd-20190930_cal XML 195K
7: EX-101.DEF XBRL Definitions -- abmd-20190930_def XML 363K
8: EX-101.LAB XBRL Labels -- abmd-20190930_lab XML 1.08M
9: EX-101.PRE XBRL Presentations -- abmd-20190930_pre XML 833K
5: EX-101.SCH XBRL Schema -- abmd-20190930 XSD 148K
68: JSON XBRL Instance as JSON Data -- MetaLinks 301± 489K
59: ZIP XBRL Zipped Folder -- 0001564590-19-039144-xbrl Zip 191K
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of ABIOMED, Inc., (the “Company”) for the quarter ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned Chairman, President and Chief Executive Officer and Vice President and Chief Financial Officer of the Company, certifies, to the best knowledge and belief of said signatory, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
|
/s/ TODD A. TRAPP |
|
|
Chairman, President and Chief Executive Officer (Principal Executive Officer) |
|
Vice President and Chief Financial Officer (Principal Financial Officer) |
|
Date: October 31, 2019 |
|
Date: October 31, 2019 |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/31/19 | 8-K | ||
| For Period end: | 9/30/19 | 4 | ||
| List all Filings | ||||